In December 2007, the New York Times published an article entitled "Data about Zetia risk was not fully revealed." The article claimed that Merck and Schering-Plough, the manufacturers of Zetia (aka ezetimibe), have information pertaining to the risk of liver damage when taking this cholesterol lowering medication in... Read more
I have written several articles pertaining to a new class of cholesterol controlling medicines called CETP (cholesterol ester transfer protein) inhibitors. CETP inhibitors can markedly raise good HDL cholesterol and moderately lower bad LDL. Most recently, all my articles have been negative given that the most clinically tested drug of this... Read more
In the beginning of this year, I wrote two articles concerning torcetrapib, the $800 million failure of Pfizer to develop a new type of cholesterol medication. This novel medication called a CETP (cholesterol ester transfer protein) inhibitor is able to markedly raise HDL, but unfortunately was found to increase the risk of death. The... Read more
High cholesterol, specifically high LDL and low HDL, is clearly a risk factor for the development of heart disease, heart attack, and death. High cholesterol promotes the development of atherosclerosis or fatty plaques in the heart arteries. The blood flow to the heart muscle can then be slowly interrupted by this gradual narrowing or suddenly... Read more